Dinender Singla, a professor at the University of Central Florida (UCF), has developed a novel technology that utilizes exosomes—tiny cell-derived vesicles—to deliver targeted treatments for cancer and heart disease. This innovative system encapsulates drugs within exosomes and coats them with specific markers to direct them to precise areas in the body, enhancing treatment efficacy while minimizing side effects. Singla’s research is particularly focused on addressing heart damage caused by cancer therapies, such as chemotherapy and radiation, which can lead to inflammation and further complications. The technology has shown promising results in laboratory settings, especially against triple-negative breast cancer, which has a notably low survival rate. To facilitate the transition from research to clinical use, Singla has partnered with Chakri Toleti, a healthcare technology entrepreneur, to form Exomic, a company dedicated to advancing this technology through funding and development. This collaboration exemplifies UCF's commitment to fostering innovation and translating academic research into impactful medical solutions. With ongoing support, the team aims to initiate FDA clinical trials, potentially revolutionizing treatment for millions suffering from these diseases.